FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)

CB-010 - Caribou Biosci

cyclophosphamide - Generic mfg.

fludarabine IV - Generic mfg.

Actemra IV (tocilizumab) - Roche, JW Pharma

https://library.ehaweb.org/eha/2022/eha2022-congress/358312/loretta.j.nastoupil.first-in-human.trial.of.cb-010.a.crispr-edited.allogeneic.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2233%2Aot_id%3D26864%2Amarker%3D1769%2Afeatured%3D17676

Loretta J. Nastoupil; Susan O'Brien; Houston E. Holmes; Ly Dsouza; Doug Hart; Emiri Matsuda; Tarah Satterfield-Ledbetter; Justin Skoble; Elizabeth Garner; Mara Bryan; Steven Kanner; Ella Li; Cherry T. Thomas; James Essell

May 13, 2022